ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF 5,8,14-TRIAZATETRACYCLO 10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE

ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF 5,8,14-TRIAZATETRACYCLO 10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE

The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ROY, MICHAEL CHRISTOPHER, SMITH, SCOTT WENDELL, QUAN, ERNEST SHING, MOSES, SARA KRISTEN, WATERMAN, KENNETH CRAIG, AM ENDE, MARY TANYA
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.